R.H. Dinel Investment Counsel Inc. Trims Stock Position in Thermo Fisher Scientific Inc. $TMO

R.H. Dinel Investment Counsel Inc. trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,921 shares of the medical research company’s stock after selling 1,825 shares during the quarter. Thermo Fisher Scientific makes up approximately 7.6% of R.H. Dinel Investment Counsel Inc.’s holdings, making the stock its 3rd largest position. R.H. Dinel Investment Counsel Inc.’s holdings in Thermo Fisher Scientific were worth $10,384,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its holdings in shares of Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after purchasing an additional 988 shares during the period. Revolve Wealth Partners LLC boosted its holdings in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after buying an additional 20 shares during the period. Level Four Advisory Services LLC grew its position in shares of Thermo Fisher Scientific by 16.0% during the 2nd quarter. Level Four Advisory Services LLC now owns 1,209 shares of the medical research company’s stock valued at $490,000 after buying an additional 167 shares during the last quarter. West Family Investments Inc. raised its stake in Thermo Fisher Scientific by 31.9% during the second quarter. West Family Investments Inc. now owns 1,187 shares of the medical research company’s stock worth $481,000 after acquiring an additional 287 shares during the period. Finally, Dixon Mitchell Investment Counsel Inc. lifted its holdings in Thermo Fisher Scientific by 38.6% in the second quarter. Dixon Mitchell Investment Counsel Inc. now owns 209,712 shares of the medical research company’s stock worth $85,145,000 after acquiring an additional 58,358 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,000 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the sale, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $63,499,170. The trade was a 3.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $541.20, for a total transaction of $216,480.00. Following the completion of the transaction, the executive vice president owned 20,752 shares of the company’s stock, valued at $11,230,982.40. This trade represents a 1.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.33% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities analysts have recently commented on TMO shares. Morgan Stanley upped their target price on Thermo Fisher Scientific from $656.00 to $670.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. HSBC upgraded Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Monday, December 1st. KeyCorp raised Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 target price on the stock in a research report on Sunday, December 7th. DZ Bank started coverage on shares of Thermo Fisher Scientific in a report on Friday. They set a “buy” rating and a $610.00 price target for the company. Finally, Robert W. Baird set a $653.00 price target on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $632.50.

Thermo Fisher Scientific Stock Up 0.1%

TMO opened at $473.83 on Monday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.89 and a quick ratio of 1.53. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99. The stock’s 50 day moving average price is $530.10 and its 200 day moving average price is $548.29. The stock has a market cap of $176.02 billion, a P/E ratio of 26.71, a P/E/G ratio of 2.73 and a beta of 0.96.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.45 by $0.12. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The company had revenue of $12.22 billion during the quarter, compared to analysts’ expectations of $11.95 billion. During the same quarter in the prior year, the business posted $6.10 earnings per share. The company’s revenue for the quarter was up 7.2% compared to the same quarter last year. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 15th. Investors of record on Friday, March 13th will be given a $0.47 dividend. The ex-dividend date is Friday, March 13th. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. Thermo Fisher Scientific’s payout ratio is currently 10.60%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.